Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PETAL: Subcutaneous anifrolumab in pediatric systemic lupus erythematosus
jRCT2031260511Recruiting
- Sponsor
- AstraZeneca
- Start
- Nov 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Open-label trial of anifrolumab in systemic lupus erythematosus (SLE) (2 cohorts), sponsored by AstraZeneca. Primary endpoint: Pharmacokinetics of anifrolumab after first dose and at steady state. Started Nov 2026; status: recruiting.
02
Drugs
anifrolumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on jRCT2031260511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260511.